Search
Unicycive Therapeutics Inc
UNCYAdd to Watchlist
5.730USD
+0.450+8.52%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
152.99MMarket Cap
LossP/E TTM
More Details of Unicycive Therapeutics Inc Company
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Unicycive Therapeutics Inc Info
Ticker SymbolUNCY
Company nameUnicycive Therapeutics Inc
IPO dateJun 17, 2021
CEOGupta (Shalabh)
Number of employees22
Security typeOrdinary Share
Fiscal year-endJun 17
Address4300 El Camino Real, Suite 210
CityLOS ALTOS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94022
Phone16503840642
Websitehttps://unicycive.com/
Ticker SymbolUNCY
IPO dateJun 17, 2021
CEOGupta (Shalabh)
Company Executives of Unicycive Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Unicycive Therapeutics Inc?
The top five shareholders of Unicycive Therapeutics Inc are: Dr. Sandeep (Steve) Laumas, M.D.
How many institutions hold shares of Unicycive Therapeutics Inc (UNCY)?
As of 2026Q1, 75 institutions hold shares of Unicycive Therapeutics Inc, with a combined market value of approximately 9.56M, accounting for 35.81% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 450872.00.